tiprankstipranks
Trending News
More News >
Claritas Pharmaceuticals (CLAZF)
OTHER OTC:CLAZF
US Market

Claritas Pharmaceuticals (CLAZF) Ratios

Compare
24 Followers

Claritas Pharmaceuticals Ratios

CLAZF's free cash flow for Q3 2021 was $0.00. For the 2021 fiscal year, CLAZF's free cash flow was decreased by $ and operating cash flow was $0.00. See a summary of the company’s cash flow.
Ratios
TTM
Dec 20Dec 19Dec 18Dec 17
Liquidity Ratios
Current Ratio
0.14 0.03---
Quick Ratio
0.14 0.03---
Cash Ratio
<0.01 <0.01---
Solvency Ratio
0.45 -0.41---
Operating Cash Flow Ratio
-0.04 -1.13---
Short-Term Operating Cash Flow Coverage
-0.33 -17.86---
Net Current Asset Value
$ -7.96M$ -28.54M---
Leverage Ratios
Debt-to-Assets Ratio
0.09 0.03---
Debt-to-Equity Ratio
0.61 -0.21---
Debt-to-Capital Ratio
0.38 -0.27---
Long-Term Debt-to-Capital Ratio
0.00 -0.12---
Financial Leverage Ratio
6.93 -7.35---
Debt Service Coverage Ratio
1.82 -8.52---
Interest Coverage Ratio
-14.56 -123.81---
Debt to Market Cap
252.80 1.76---
Interest Debt Per Share
0.04 0.04---
Net Debt to EBITDA
-0.33 -0.07---
Profitability Margins
Gross Profit Margin
0.00%0.00%---
EBIT Margin
0.00%0.00%---
EBITDA Margin
0.00%0.00%---
Operating Profit Margin
0.00%0.00%---
Pretax Profit Margin
0.00%0.00%---
Net Profit Margin
0.00%0.00%---
Continuous Operations Profit Margin
0.00%0.00%---
Net Income Per EBT
-624.63%82.11%---
EBT Per EBIT
20.57%99.84%---
Return on Assets (ROA)
40.31%-83.99%---
Return on Equity (ROE)
-436.27%617.17%---
Return on Capital Employed (ROCE)
-98.76%-132.75%---
Return on Invested Capital (ROIC)
482.39%-107.00%---
Return on Tangible Assets
429.15%-13175.16%---
Earnings Yield
157731.07%-5081.98%---
Efficiency Ratios
Receivables Turnover
0.00 0.00---
Payables Turnover
0.00 0.00---
Inventory Turnover
0.00 0.00---
Fixed Asset Turnover
0.00 0.00---
Asset Turnover
0.00 0.00---
Working Capital Turnover Ratio
0.00 0.00---
Cash Conversion Cycle
0.00 0.00---
Days of Sales Outstanding
0.00 0.00---
Days of Inventory Outstanding
0.00 0.00---
Days of Payables Outstanding
0.00 0.00---
Operating Cycle
0.00 0.00---
Cash Flow Ratios
Operating Cash Flow Per Share
-0.01 -0.29---
Free Cash Flow Per Share
-0.01 -0.29---
CapEx Per Share
0.00 0.00---
Free Cash Flow to Operating Cash Flow
1.00 1.00---
Dividend Paid and CapEx Coverage Ratio
0.00 0.00---
Capital Expenditure Coverage Ratio
0.00 0.00---
Operating Cash Flow Coverage Ratio
-0.33 -8.81---
Operating Cash Flow to Sales Ratio
0.00 0.00---
Free Cash Flow Yield
-8444.93%-1553.20%---
Valuation Ratios
Price-to-Earnings (P/E) Ratio
<0.01 -0.02---
Price-to-Sales (P/S) Ratio
0.00 0.00---
Price-to-Book (P/B) Ratio
<0.01 -0.12---
Price-to-Free Cash Flow (P/FCF) Ratio
-0.01 -0.06---
Price-to-Operating Cash Flow Ratio
>-0.01 -0.06---
Price-to-Earnings Growth (PEG) Ratio
<0.01 <0.01---
Price-to-Fair Value
<0.01 -0.12---
Enterprise Value Multiple
-0.33 -0.12---
Enterprise Value
923.66K 1.12M---
EV to EBITDA
-0.33 -0.12---
EV to Sales
0.00 0.00---
EV to Free Cash Flow
-2.99 -0.17---
EV to Operating Cash Flow
-2.99 -0.17---
Tangible Book Value Per Share
-0.30 -1.27---
Shareholders’ Equity Per Share
0.06 -0.15---
Tax and Other Ratios
Effective Tax Rate
7.25 0.18---
Revenue Per Share
0.00 0.00---
Net Income Per Share
0.16 -0.95---
Tax Burden
-6.25 0.82---
Interest Burden
-3.66 0.99---
Research & Development to Revenue
0.00 0.00---
SG&A to Revenue
0.00 0.00---
Stock-Based Compensation to Revenue
0.00 0.00---
Income Quality
-0.07 0.31---
Currency in USD